The AstraZeneia vaccine protects the elderly, and the 10-year-old drug promises to treat patients with severe new crowns

The results of the vaccine from AstraZeneta and Oxford University are published in The Lancet.
the vaccine uses the adenovirus ChAdOx1 as a vector to express the prickly protein of the new coronavirus.
team has previously assessed its effectiveness among young people, and the study has expanded to a broader group, including those aged 70 and over.
study showed that the group's IgG response and moderate antibody titration were comparable to 18-55 years of age, or 56-69 years of age.
in terms of tolerance, the vaccine appears to perform better in older groups.
Professor Mahshi Ramasamy, of the University of Oxford, who is studying the study, points out that older people are at high risk of coronary disease and that vaccines are generally less effective at immunized against them.
the results of this study suggest that the new adenovirus crown vaccine is not only well-mmune in older populations, but also provides a similar immune response to younger populations, which is good news.
future, researchers plan to assess whether the vaccine can actually prevent the disease.
Roche's tocilizumab is a monoclonal antibody that binds to the IL-6 receptor and blocks the IL-6 signaling path, thereby blocking an inflammatory response.
as early as 2010, it was approved by the U.S. FDA for listing to treat rheumatoid arthritis.
considering that many patients with neo-coronary disease have an overactive immune response, the potential for its treatment of new coronary patients is also being evaluated.
earlier this year, some studies suggested that such drugs appeared to be ineffective.
but today a large study, REMAP-CAP, came to the opposite conclusion.
the study, which assessed the effectiveness of different drugs on new crown patients at 200 sites in 19 countries around the world, showed that tocilizumab reached a critical therapeutic endpoint in severe neo crown patients.
patients who received tocilizumab were more likely to improve their condition than those who did not receive immunomodulation agents.
the study has not been peer-reviewed because other efficacy has not been analyzed.
, but given the clinical implications of the findings, the researchers decided to publish their findings in advance.
news about BioNTech's vaccine in partnership with Pfizer.
an interview with CNN, BioNTech's chief executive, Dr. Uur Sahin, said he would submit his vaccine application for EUA on Friday local time.
week, the two companies released data on the vaccine, noting that the vaccine is up to 95 percent effective and will be submitted "within days."
now, we have an exact date.
news that vaccine development usually takes years, but the vaccine's EUA application is only 11 months away from understanding the new coronavirus.
the usual review process takes several weeks after the EUA application is submitted.
FDA's reviewers will send the data to the advisory board for discussion and advice.
moderna's new crown vaccine plans to submit an application to the FDA after the final results analysis is completed.
, Moderna's chief executive, said an advisory board meeting, to be held from December 8-10, was expected to discuss the BioNTech/Pfizer vaccine as well as moderna's vaccine.
if the results are positive, they will be the first two new crown vaccines reviewed by the FDA and the first two mRNA vaccines reviewed by the FDA.
: s1? Maheshi N Ramasamy et al., (2020), Safety and immunogenicity of chAdOx1 nCoV-19 vaccine a prime-boost regimen in young and old adults (COV002): a single-blind, randomized, controlled, phase 2/3 trial, The Lancet, DOI: s.2. Oxford coronavirus vaccine produces strong immune response in older adults, Retrieved November 19, 2020, from s.3. Arthritis drug effective in treating sickest COVID-19 patients, Retrieved November 19, 2020, from [4] A new study breathes life into an all-but-dead approach to treating severe Covid-19, Retrieved November 19, 2020, from [5] CEO Ugur Sahin: BioNTech and Pfizer will file for a Covid-19 vaccine EUA on Friday, , Retrieved November 19, 2020, from